Andere talen China Grand Pha.and Healthcare Hld. Ltd. Hong Kong S.E.

Aandelen

0512

BMG210A71198

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Grand Pharmaceutical Group Enrolls First Patient in Phase 1 Study for Myopia Eye Drops in China	12/06
Grand Pharmaceutical Group Limited Announces the Phase I Clinical Study Conducted in China of the Groups Global Innovative Ophthalmic Drug Gpn00884 Has Completed the First Patient Enrollment	11/06
Grand Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023	04/06
Grand Pharmaceutical's Profit Down 10% in 2023 Despite 10% Revenue Jump	29/04
Grand Pharmaceutical Group Limited Enters into Strategic Cooperation Agreement for Product Introduction with LianBio Development (HK) Limited and Tarsus Pharmaceuticals, Inc	27/03
Grand Pharma Receives Green Light for Phase III Trials of Cancer Drug	25/03
Grand Pharmaceutical Group Limited Announces That ITM-11, A Global Innovative Radionuclide-Drug Conjugate of the Group for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors	24/03
Grand Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 27 June 2024	19/03
Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Grand Pharmaceutical Group's Partner Gets FDA Approval for Eye Medication	08/03
Grand Pharmaceutical Group's Children's Myopia Drug Approved for Phase I Trial	08/03
Grand Pharmaceutical Group Limited Announces Update on Global Innovative Ophthalmic Drug GPN00884	07/03
Grand Pharmaceutical's New Drug Application for Antihistamine Nasal Spray Accepted in China	08/02
Grand Pharmaceutical Unit's Investigational New Drug Application for Tumor Vaccine Gets Nod from Chinese Regulator	24/01
Grand Pharmaceutical's Unit Further Acquires Stake in Chongqing Duoputai Pharmaceutical for 442.26 Million Yuan	16/01
Grand Pharmaceutical Secures Chinese Approval for Phase 1 Trial of Eye Drops	27/12
Grand Pharmaceutical Group Limited Announces the Investigational New Drug Application in China of the Group's Global Innovative Ophthalmic Drug GPN00884 Was Accepted by NMPA	27/12
Grand Pharmaceutical's Unit Acquires Controlling Stake in Tianjin Tanabe Seiyaku for HK$400 Million	22/12
Grand Pharmaceutical's Subsidiaries to Resell Sirtex's Products for 166.5 Million Yuan	18/12
Grand Pharmaceutical Buys 27% of Duoputai Pharmaceutical Technology for 189.54 Million Yuan	13/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen China Grand Pha.and Healthcare Hld. Ltd. Hong Kong S.E.

Aandelen

0512

BMG210A71198

Andere talen

Filters